Display options
Cite
Helgadottir H, Rocha Trocoli Drakensjö I, Girnita A. Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment. Front Oncol. 2018;8:202doi: 10.3389/fonc.2018.00202.
Helgadottir, H., Rocha Trocoli Drakensjö, I., & Girnita, A. (2018). Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment. Frontiers in oncology, 8202. https://doi.org/10.3389/fonc.2018.00202
Helgadottir, Hildur, et al. "Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment." Frontiers in oncology vol. 8 (2018): 202. doi: https://doi.org/10.3389/fonc.2018.00202
Helgadottir H, Rocha Trocoli Drakensjö I, Girnita A. Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment. Front Oncol. 2018 Jun 12;8:202. doi: 10.3389/fonc.2018.00202. eCollection 2018. PMID: 29946532; PMCID: PMC6006716.
Copy Download .nbib Format: NLM
Share it on

Front Oncol. 2018 Jun 12;8:202. doi: 10.3389/fonc.2018.00202. eCollection 2018.

Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment.

Frontiers in oncology

Hildur Helgadottir, Iara Rocha Trocoli Drakensjö, Ada Girnita

Affiliations

  1. Skin Tumor Center, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden.
  2. Cancer Centrum Karolinska, Karolinska Institutet Stockholm, Stockholm, Sweden.

PMID: 29946532 PMCID: PMC6006716 DOI: 10.3389/fonc.2018.00202

Abstract

Despite enormous international efforts, skin melanoma is still a major clinical challenge. Melanoma takes a top place among the most common cancer types and it has one of the most rapidly increasing incidences in many countries around the world. Until recent years, there have been limited options for effective systemic treatment of disseminated melanoma. However, lately, we have experienced a rapid advancement in the understanding of the biology and molecular background of the disease. This has led to new molecular classifications and the development of more effective targeted therapies adapted to distinct melanoma subtypes. Not only are these treatments more effective but they can be rationally prescribed to the patients standing to benefit. As such, melanoma management has now become one of the most developed for personalized medicine. The aim of the present paper is to summarize the current knowledge on melanoma molecular classification, predictive markers, combination therapies, as well as emerging new treatments.

Keywords: functional selectivity; melanoma; receptor tyrosine kinases; signaling; targeted therapy; ubiquitination

References

  1. ACS Med Chem Lett. 2017 Mar 06;8(5):486-491 - PubMed
  2. Semin Cell Dev Biol. 2018 Jun;78:73-84 - PubMed
  3. Cancer. 2010 Nov 1;116(21):4902-13 - PubMed
  4. Cancer Res. 2000 Sep 15;60(18):5278-83 - PubMed
  5. Discov Med. 2016 Apr;21(116):267-74 - PubMed
  6. Dermatol Clin. 2016 Oct;34(4):421-429 - PubMed
  7. Nat Rev Cancer. 2012 Mar 22;12(4):237-51 - PubMed
  8. Nat Rev Clin Oncol. 2017 Aug;14 (8):463-482 - PubMed
  9. Cancer Res. 2004 Jan 1;64(1):236-42 - PubMed
  10. Proc Natl Acad Sci U S A. 2003 Jul 8;100(14 ):8247-52 - PubMed
  11. Chin Clin Oncol. 2014 Sep;3(3):35 - PubMed
  12. Lancet Oncol. 2010 Feb;11(2):105-6 - PubMed
  13. Clin Cancer Res. 2017 Aug 15;23 (16):4938-4944 - PubMed
  14. J Invest Dermatol. 2016 Oct;136(10 ):1955-1960 - PubMed
  15. BMC Syst Biol. 2017 Jul 19;11(1):70 - PubMed
  16. P T. 2012 Sep;37(9):503-30 - PubMed
  17. J Clin Invest. 2007 May;117(5):1137-46 - PubMed
  18. Br J Ophthalmol. 2009 Nov;93(11):1524-8 - PubMed
  19. Mol Cell Endocrinol. 2000 Jul 25;165(1-2):131-7 - PubMed
  20. Nat Rev Cancer. 2016 Aug;16(8):508-24 - PubMed
  21. Lakartidningen. 2013 Feb 20-26;110(8):410-2 - PubMed
  22. Science. 1994 Mar 4;263(5151):1281-4 - PubMed
  23. J Dermatol Case Rep. 2014 Sep 30;8(3):60-6 - PubMed
  24. Ann Oncol. 2016 Oct;27(10 ):1959-65 - PubMed
  25. Clin Cancer Res. 2002 Nov;8(11):3584-91 - PubMed
  26. Clin Cancer Res. 2015 Jan 1;21(1):77-86 - PubMed
  27. Clin Cancer Res. 2008 Nov 1;14(21):6821-8 - PubMed
  28. Cancer Res. 2008 Sep 1;68(17 ):6953-62 - PubMed
  29. Ann Surg Oncol. 2007 Oct;14(10):2854-60 - PubMed
  30. CA Cancer J Clin. 2017 Nov;67(6):472-492 - PubMed
  31. Prog Mol Biol Transl Sci. 2016;141:277-311 - PubMed
  32. Oncogene. 2017 Oct 12;36(41):5734-5744 - PubMed
  33. Nat Rev Drug Discov. 2009 Sep;8(9):709-23 - PubMed
  34. Arch Dermatol. 2009 Apr;145(4):427-34 - PubMed
  35. J Am Acad Dermatol. 1995 Dec;33(6):923-36; quiz 937-40 - PubMed
  36. J Invest Dermatol. 2018 Feb;138(2):254-255 - PubMed
  37. Nature. 2002 Jun 27;417(6892):949-54 - PubMed
  38. Cancer. 2005 Mar 1;103(5):1000-7 - PubMed
  39. Br J Plast Surg. 2002 Dec;55(8):611-5 - PubMed
  40. Arch Surg. 1997 May;132(5):553-6 - PubMed
  41. Oncogene. 2017 Jun 8;36(23 ):3274-3286 - PubMed
  42. Oncoimmunology. 2017 Sep 21;7(1):e1365209 - PubMed
  43. Oncotarget. 2017 Jul 17;8(47):82256-82267 - PubMed
  44. Cancer. 1968 May;21(5):893-911 - PubMed
  45. IUBMB Life. 2007 Jul;59(7):419-26 - PubMed
  46. J Biol Chem. 2007 Apr 13;282(15):11329-38 - PubMed
  47. Immunol Cell Biol. 2006 Jun;84(3):295-302 - PubMed
  48. Cell. 2015 Jun 18;161(7):1681-96 - PubMed
  49. Proc Natl Acad Sci U S A. 2012 May 1;109 (18):7055-60 - PubMed
  50. Cancer Lett. 2003 Jun 10;195(2):127-37 - PubMed
  51. Oncogene. 1992 Jan;7(1):51-6 - PubMed
  52. N Engl J Med. 2014 Nov 13;371(20):1877-88 - PubMed
  53. Growth Horm IGF Res. 2015 Feb;25(1):2-12 - PubMed
  54. Clin Cancer Res. 2006 Feb 15;12(4):1383-91 - PubMed
  55. Int J Cancer. 2016 Jul 1;139(1):75-84 - PubMed
  56. Br J Dermatol. 2014 Jan;170(1):52-8 - PubMed
  57. Melanoma Res. 2003 Aug;13(4):325-37 - PubMed
  58. Mayo Clin Proc. 2014 Jan;89(1):52-9 - PubMed
  59. Anticancer Drug Des. 2000 Feb;15(1):67-72 - PubMed
  60. Exp Cell Res. 1999 Jan 10;246(1):38-46 - PubMed
  61. Int J Cancer. 1992 Sep 9;52(2):197-201 - PubMed
  62. Int J Cancer. 2018 May 15;142(10 ):2139-2152 - PubMed
  63. BMC Cancer. 2017 Aug 17;17 (1):551 - PubMed
  64. Nat Genet. 2011 Aug 28;43(10 ):1018-21 - PubMed
  65. Semin Cutan Med Surg. 2011 Dec;30(4):222-8 - PubMed
  66. Head Neck. 2016 Jan;38(1):147-55 - PubMed
  67. Invest Ophthalmol Vis Sci. 2008 Jun;49(6):2337-42 - PubMed
  68. Pigment Cell Melanoma Res. 2011 Jun;24(3):446-61 - PubMed
  69. Pigment Cell Melanoma Res. 2016 Jul;29(4):404-16 - PubMed
  70. Cancer Discov. 2016 Jul;6(7):740-53 - PubMed
  71. Invest Ophthalmol Vis Sci. 2004 Jul;45(7):2075-82 - PubMed
  72. J Clin Oncol. 2011 Mar 1;29(7):917-24 - PubMed
  73. Invest Ophthalmol Vis Sci. 2008 Jun;49(6):2620-6 - PubMed
  74. Crit Rev Oncog. 2016;21(1-2):141-54 - PubMed
  75. J Cell Physiol. 1997 Nov;173(2):275-8 - PubMed
  76. Dermatol Surg. 2006 Apr;32(4):493-504 - PubMed
  77. Int J Cancer. 1997 Jul 17;72(2):231-5 - PubMed
  78. Nat Rev Cancer. 2013 Mar;13(3):153-9 - PubMed
  79. Cell. 2012 Jul 20;150(2):251-63 - PubMed
  80. J Am Acad Dermatol. 2012 Jul;67(1):60-8 - PubMed
  81. Science. 1998 Jan 23;279(5350):577-80 - PubMed
  82. Cancer Res. 2016 Oct 1;76(19):5634-5646 - PubMed
  83. J Natl Cancer Inst. 1997 May 21;89(10):697-702 - PubMed
  84. J Cell Biol. 2005 Aug 29;170(5):703-8 - PubMed
  85. Nature. 1974 Sep 13;251(5471):161-3 - PubMed
  86. Nat Rev Dis Primers. 2015 Apr 23;1:15003 - PubMed
  87. Clin Cancer Res. 2015 Jul 15;21(14):3113-20 - PubMed
  88. Oncogene. 2008 Mar 6;27(11):1629-38 - PubMed
  89. Invest Ophthalmol Vis Sci. 2006 Jan;47(1):72-7 - PubMed
  90. N Engl J Med. 2015 Jan 22;372(4):320-30 - PubMed
  91. Nat Rev Clin Oncol. 2012 Apr 17;9(6):338-50 - PubMed
  92. Mol Pharmacol. 2008 Mar;73(3):930-9 - PubMed
  93. PLoS One. 2012;7(4):e35295 - PubMed
  94. Clin Cancer Res. 2009 Jan 1;15(1):324-9 - PubMed
  95. Nature. 2009 Jan 29;457(7229):599-602 - PubMed
  96. J Hematol Oncol. 2016 Mar 08;9:19 - PubMed
  97. Oncogene. 2003 May 19;22(20):3113-22 - PubMed
  98. Dermatol Ther. 2008 Nov-Dec;21(6):439-46 - PubMed
  99. N Engl J Med. 2011 Feb 24;364(8):710-8 - PubMed
  100. Curr Treat Options Oncol. 2015 Apr;16(4):15 - PubMed
  101. Cancer Lett. 2014 Mar 1;344(1):1-12 - PubMed
  102. Cancer. 1996 Apr 1;77(7):1303-10 - PubMed
  103. J Am Acad Dermatol. 2002 Nov;47(5):743-8 - PubMed
  104. Science. 2003 Apr 11;300(5617):286-90 - PubMed
  105. J Biol Chem. 2005 Jul 1;280(26):24412-9 - PubMed
  106. Am J Pathol. 1999 Jun;154(6):1643-7 - PubMed
  107. Clin Cancer Res. 2016 Jun 15;22(12 ):2897-907 - PubMed
  108. Arch Dermatol. 1991 Mar;127(3):421 - PubMed
  109. N Engl J Med. 2011 Jun 30;364(26):2507-16 - PubMed
  110. Nat Commun. 2017 Sep 27;8(1):707 - PubMed
  111. BioDrugs. 2017 Feb;31(1):51-61 - PubMed
  112. J Surg Res. 2007 Jul;141(1):72-7 - PubMed
  113. Br J Dermatol. 1987 Mar;116(3):303-10 - PubMed
  114. Science. 2013 Feb 22;339(6122):959-61 - PubMed
  115. Mol Cancer Ther. 2012 Sep;11(9):1905-14 - PubMed
  116. JAMA Dermatol. 2017 Dec 1;153(12 ):1278-1284 - PubMed
  117. Nature. 2013 Aug 22;500(7463):415-21 - PubMed
  118. Curr Opin Oncol. 2017 Nov;29(6):484-492 - PubMed
  119. Lancet Oncol. 2015 Aug;16(8):908-18 - PubMed
  120. Mayo Clin Proc. 2012 Oct;87(10):991-1003 - PubMed
  121. J Clin Oncol. 2016 Dec;34(34):4102-4109 - PubMed
  122. Lancet. 2012 Jul 28;380(9839):358-65 - PubMed
  123. Exp Dermatol. 2016 Nov;25(11):831-838 - PubMed
  124. Cancer Res. 2008 Jul 15;68(14 ):5669-77 - PubMed
  125. Invest Ophthalmol Vis Sci. 2002 Jan;43(1):1-8 - PubMed
  126. J Clin Oncol. 2008 Nov 10;26(32):5233-9 - PubMed
  127. Annu Rev Immunol. 2006;24:771-800 - PubMed
  128. Nat Rev Clin Oncol. 2018 Mar;15(3):183-192 - PubMed
  129. J Clin Oncol. 2014 May 1;32(13):1356-64 - PubMed
  130. Biochem Biophys Res Commun. 2012 Jun 22;423(1):122-7 - PubMed
  131. Am J Clin Dermatol. 2005;6(3):151-64 - PubMed
  132. Clin Dermatol. 2013 Mar-Apr;31(2):141-7 - PubMed
  133. J Immunother. 2008 Oct;31(8):742-51 - PubMed
  134. J Clin Invest. 1993 Oct;92(4):1736-44 - PubMed
  135. Oncogene. 1996 Dec 5;13(11):2339-47 - PubMed
  136. Br J Dermatol. 2018 Feb;178(2):443-451 - PubMed
  137. Oncogene. 2012 Jan 19;31(3):352-65 - PubMed
  138. Cancer Chemother Pharmacol. 2017 Jun;79(6):1187-1193 - PubMed
  139. Annu Rev Immunol. 2004;22:329-60 - PubMed
  140. Proc Natl Acad Sci U S A. 2012 Dec 11;109 (50):20620-5 - PubMed
  141. Trends Mol Med. 2006 Sep;12(9):406-14 - PubMed
  142. Mol Cancer Ther. 2013 Dec;12(12):2817-26 - PubMed
  143. N Engl J Med. 1998 Mar 26;338(13):879-87 - PubMed
  144. Cell Mol Life Sci. 2014 Jul;71(13):2403-27 - PubMed
  145. CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30 - PubMed
  146. Cancer. 1998 Oct 15;83(8):1664-78 - PubMed
  147. PLoS One. 2016 Apr 06;11(4):e0153053 - PubMed
  148. Melanoma Res. 2011 Aug;21(4):357-63 - PubMed
  149. Int J Cancer. 2003 May 10;104(6):764-71 - PubMed
  150. J Invest Dermatol. 2005 Oct;125(4):685-91 - PubMed
  151. PLoS One. 2011 Mar 14;6(3):e14757 - PubMed
  152. Expert Opin Ther Targets. 2005 Aug;9(4):753-68 - PubMed
  153. J Clin Oncol. 2013 Sep 10;31(26):3205-11 - PubMed
  154. Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):E7240-E7249 - PubMed
  155. J Clin Pathol. 2016 Sep;69(9):750-3 - PubMed
  156. Front Endocrinol (Lausanne). 2015 Apr 27;6:64 - PubMed
  157. Clin Cancer Res. 2018 Mar 15;24(6):1260-1270 - PubMed

Publication Types